New research at acc25 shows daxor bva-identified euvolemic heart failure patients experience 2.61 times better survival

Precise volume measurement prior to discharge identifies mortality risk oak ridge, tn, april 15, 2025 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announced compelling new data presented at the american college of cardiology (acc) 74th annual scientific session and expo held in chicago from march 29-31st. research from the minneapolis heart institute foundation® and allina health minneapolis heart institute® demonstrated that hospitalized heart failure patients who received blood volume analysis (bva) prior to hospital discharge could be used to stratify those with a substantially better survival rate.
DXR Ratings Summary
DXR Quant Ranking